• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis.

作者信息

Cavazos Karla, Eswaran Sheila, Maidlow Cathleen, Keklik Karadag Fatma, Idilman Ramazan, Idilman Ilkay, Miller Ira, Shammo Jamile, Reau Nancy, Ustun Celalettin

机构信息

Division of Hematology, Oncology, and Cellular Therapy, Department of Medicine, Rush University Medical Center, Chicago, IL.

Division of Gastroenterology, Hepatology, and Nutrition, Rush University Medical Center, Chicago, IL.

出版信息

Blood Adv. 2022 Oct 25;6(20):5630-5633. doi: 10.1182/bloodadvances.2022008038.

DOI:10.1182/bloodadvances.2022008038
PMID:35839085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9647789/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36b2/9647789/7a5a29c51fc0/BLOODA_ADV-2022-008038-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36b2/9647789/40336e5d784e/BLOODA_ADV-2022-008038-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36b2/9647789/c4d1ac1eb0b3/BLOODA_ADV-2022-008038-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36b2/9647789/7a5a29c51fc0/BLOODA_ADV-2022-008038-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36b2/9647789/40336e5d784e/BLOODA_ADV-2022-008038-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36b2/9647789/c4d1ac1eb0b3/BLOODA_ADV-2022-008038-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36b2/9647789/7a5a29c51fc0/BLOODA_ADV-2022-008038-gr2.jpg

相似文献

1
Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis.2例系统性肥大细胞增多症患者的肝纤维化及其对阿伐替尼的反应
Blood Adv. 2022 Oct 25;6(20):5630-5633. doi: 10.1182/bloodadvances.2022008038.
2
Avapritinib for advanced systemic mastocytosis.阿伐普利替尼治疗晚期系统性肥大细胞增生症。
Blood. 2022 Oct 13;140(15):1667-1673. doi: 10.1182/blood.2021014612.
3
Avapritinib for Systemic Mastocytosis.阿伐普利替尼治疗系统性肥大细胞增生症。
Expert Rev Hematol. 2021 Aug;14(8):687-696. doi: 10.1080/17474086.2021.1959315. Epub 2021 Aug 6.
4
Avapritinib in the Treatment of Systemic Mastocytosis: an Update.阿伐普利替尼治疗系统性肥大细胞增生症：更新。
Curr Hematol Malig Rep. 2021 Oct;16(5):464-472. doi: 10.1007/s11899-021-00650-4. Epub 2021 Sep 27.
5
Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.阿伐替尼与米哚妥林用于晚期系统性肥大细胞增多症患者的间接治疗比较。
Future Oncol. 2022 Apr;18(13):1583-1594. doi: 10.2217/fon-2021-1509. Epub 2022 Feb 4.
6
Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy.阿伐替尼治疗侵袭性系统性肥大细胞增多症的克隆动力学
Blood Cancer J. 2024 Oct 14;14(1):179. doi: 10.1038/s41408-024-01157-w.
7
Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.晚期系统性肥大细胞增多症的反应标准：在 KIT 抑制剂时代的演变。
Int J Mol Sci. 2021 Mar 15;22(6):2983. doi: 10.3390/ijms22062983.
8
Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: Prompt resolution of anaphylaxis with the addition of avapritinib.系统性肥大细胞增多症伴相关血液系统肿瘤并并发复发性过敏反应：加用阿伐替尼后过敏反应迅速缓解
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2534-2536. doi: 10.1016/j.jaip.2021.02.040. Epub 2021 Mar 4.
9
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.在晚期系统性肥大细胞增多症中阿伐普利替尼的安全性和疗效：EXPLORER 期试验。
Nat Med. 2021 Dec;27(12):2183-2191. doi: 10.1038/s41591-021-01538-9. Epub 2021 Dec 6.
10
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.阿伐普利替尼对比最佳可用疗法治疗晚期系统性肥大细胞增多症的疗效。
Leukemia. 2022 Aug;36(8):2108-2120. doi: 10.1038/s41375-022-01615-z. Epub 2022 Jul 5.

引用本文的文献

1
Systemic mastocytosis: current status and challenges in 2024.系统性肥大细胞增多症：2024年的现状与挑战
Blood Adv. 2025 May 13;9(9):2048-2062. doi: 10.1182/bloodadvances.2024012612.
2
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.异基因造血细胞移植治疗晚期系统性肥大细胞增生症：EBMT 实践协调和指南委员会代表的最佳实践建议。
Leukemia. 2024 Apr;38(4):699-711. doi: 10.1038/s41375-024-02182-1. Epub 2024 Mar 12.

本文引用的文献

1
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.肥大细胞疾病的更新诊断标准与分类：一项共识提议。
Hemasphere. 2021 Oct 13;5(11):e646. doi: 10.1097/HS9.0000000000000646. eCollection 2021 Nov.
2
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.晚期系统性肥大细胞增多症中 avapritinib 的疗效和安全性：2 期 PATHFINDER 试验的中期分析。
Nat Med. 2021 Dec;27(12):2192-2199. doi: 10.1038/s41591-021-01539-8. Epub 2021 Dec 6.
3
Systemic Mastocytosis: Multidisciplinary Approach.
系统性肥大细胞增多症：多学科诊疗方法
Mediterr J Hematol Infect Dis. 2021 Nov 1;13(1):e2021068. doi: 10.4084/MJHID.2021.068. eCollection 2021.
4
Avapritinib for Systemic Mastocytosis.阿伐普利替尼治疗系统性肥大细胞增生症。
Expert Rev Hematol. 2021 Aug;14(8):687-696. doi: 10.1080/17474086.2021.1959315. Epub 2021 Aug 6.
5
Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.首届美国肥大细胞疾病倡议（AIM）研究者会议论文集。
J Allergy Clin Immunol. 2021 Jun;147(6):2043-2052. doi: 10.1016/j.jaci.2021.03.008. Epub 2021 Mar 11.
6
MR elastography of liver: current status and future perspectives.肝脏磁共振弹性成像：现状与未来展望
Abdom Radiol (NY). 2020 Nov;45(11):3444-3462. doi: 10.1007/s00261-020-02656-7. Epub 2020 Jul 23.
7
ACR Appropriateness Criteria® Chronic Liver Disease.美国放射学会适宜性标准® 慢性肝病
J Am Coll Radiol. 2020 May;17(5S):S70-S80. doi: 10.1016/j.jacr.2020.01.023.
8
Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.高级系统性肥大细胞增多症：从分子和遗传学进展到临床实践。
Haematologica. 2016 Oct;101(10):1133-1143. doi: 10.3324/haematol.2016.146563.
9
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.中剂量伊马替尼治疗晚期系统性肥大细胞增多症的疗效和安全性。
N Engl J Med. 2016 Jun 30;374(26):2530-41. doi: 10.1056/NEJMoa1513098.
10
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.